Signal / reference entry

Liraglutide

Also listed as Saxenda

Start with the scope. Follow the sources. Use the reading note to examine how a claim is supported.

Reference fields

View sources

Approval labels are specific to a product, route, and use. Read the scope and limitations together.

Status for this entry
Approved product
Evidence label
Randomized evidence

Status as of

Product and use
Saxenda: weight management for eligible patients.
Route context
Subcutaneous injection.
Mechanism
Activates the GLP-1 receptor.
Evidence
Randomized trials.
Limitations
Check other products separately.
Safety
The label warns about severe gastrointestinal reactions.

Sources for these reference fields

Read beyond the claim

A closer reading

A claim of being better needs a reference point. If a claim uses that comparison, identify what gives it meaning and ask why that comparison was selected. Read what each group was meant to represent before comparing the reported outcomes. Consider whether another reasonable comparison would address a different question, rather than treating all alternatives as interchangeable. Your notes should state both the claim and its reference point in plain language. If you cannot describe what was compared with what, the ranking is not yet specific enough to evaluate.

Questions to take to the source

  1. What exactly serves as the reference point for this comparison?
  2. Why was that comparison chosen for the question being investigated?
  3. Would a different reference point answer a different question altogether?

Filed under

  • Metabolism

Topics organize the index; they do not describe a recommended use.

Sources

These references support the reference fields as a group. Follow each link to inspect its scope and wording.

  1. SAXENDA NLM · Checked

Educational reference material. No clinician review is claimed. This entry does not provide personal medical advice.